Behavioral Drivers of Oncologists' Treatment Practices
Emotional Influencers on Oncologists' Treatment Practices
A detailed study from OncCentral uncovers:
  • Non-clinical factors impacting treatment choice
  • Physician segments impacted by emotional factors

Biomarkers in Immuno-Oncology
Biomarkers in Immuno-Oncology:  Sorting through the Noise and Confusion
 • Uncover their relevance to your patient population and the available treatment options 
• Get a clear road map of biomarker applications and their use in diagnosis and treatment choice
 • Hear from key thought leaders to understand industry impact 

FDA Approves Pembrolizumab for Hodgkin LymphomaThe FDA has granted an accelerated approval to pembrolizumab (Keytruda) for the treatment of adult and pediatric patients with classical Hodgkin lymphoma (cHL) who are refractory or have relapsed after 3 or more lines of therapy. Read more
Abemaciclib Improves PFS in Phase III Breast Cancer TrialAdding abemaciclib to fulvestrant improved progression-free survival (PFS) compared with fulvestrant alone in women with HR+/HER2-negative breast cancer enrolled in the phase III MONARCH 2 study, according to Eli Lilly and Company, the manufacturer of the CDK4/6 inhibitor.  Read more
KOL Corner
Maintenance therapy with olaparib (Lynparza) showed a 70% reduction in the risk of progression or death compared with placebo for patients with platinum-sensitive, relapsed, BRCA-mutant ovarian cancer, according to phase III SOLO2 findings reported at the 2017 Society of Gynecologic Oncology meeting. Read more
Patient Perspective
Cancer survivor Dana Stewart discusses a conference that celebrates young adult cancer survivors.  Read more
Tell me something I don't know
After weeks of negotiations and last-minute drama, the House GOP has pulled its Obamacare replacement bill after it became clear that there were not enough votes to pass it. Read more